Evaluation of patupilone as monotherapy in patients with advanced hepatocellular carcinoma (HCC)

被引：0
|
作者：
Venook, A. P.
Poon, R.
Kang, Y. K.
Mok, T. S.
Chao, Y.
de Bedout, S.
Harbott, A.
Li, J.
Johri, A. R.
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Univ Hong Kong, Queen Mary Hosp, Hong Kong, Peoples R China
[3] Asan Med Ctr, Seoul, South Korea
[4] Chinese Univ Hong Kong, Hong Kong, Peoples R China
[5] Vet Gen Hosp, Taipei, Taiwan
[6] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15055
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Influence of underlying liver disease on response to sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Bouattour, M.
    Faivre, S. J.
    Dreyer, C.
    Paradis, V.
    Raymond, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [32] Models to Predict Development or Recurence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Hepatic Fibrosis
    Yilma M.
    Saxena V.
    Mehta N.
    Current Gastroenterology Reports, 2022, 24 (1) : 1 - 9
  • [33] Association of hypertension with overall outcome in patients taking sorafenib in advanced hepatocellular carcinoma (HCC)
    Kim, R. D.
    Byrne, M. T.
    Hammel, J.
    El-Gazzaz, G.
    Aucejo, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] A phase II study of arsenic trioxide (ATO) in patients with advanced hepatocellular carcinoma (HCC)
    Rodgers, H. A.
    Katta, S. F.
    Malani, A. K.
    Willis, M.
    Markowitz, A. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Cainap, Calin
    Qin, Shukui
    Huang, Wen-Tsung
    Chung, Ik-Joo
    Pan, Hongming
    Cheng, Ying
    Kudo, Masatoshi
    Kang, Yoon-Koo
    Chen, Pei-Jer
    Toh, Han Chong
    Gorbunova, Vera
    Eskens, Ferry
    Qian, Jiang
    McKee, Mark D.
    Ricker, Justin L.
    Carlson, Dawn M.
    El Nowiem, Saied
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [36] HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH LIVER CIRRHOSIS
    Resuli, B.
    Babameto, A.
    Basho, J.
    Shehu, K.
    Akshia, I.
    ANNALS OF ONCOLOGY, 2010, 21 : 113 - 113
  • [37] SAFETY PROFILE OF SORAFENIB (SO) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): A PROSPECTIVE EVALUATION
    Dhorancy, Sebastien
    Cattan, Stephane
    Romano, Olivier
    Conva, Valerie
    Castel, Helene
    Boleslawski, Emmanuel
    Truant, Stephanie
    Hebbar, Mohammed
    Pruvot, Francois R.
    Mathurin, Philippe
    HEPATOLOGY, 2009, 50 (04) : 1099A - 1099A
  • [38] Prognosis of patients with metastatic hepatocellular carcinoma (HCC).
    Ishii, H
    Furuse, J
    Nagase, M
    Yoshino, M
    Takahashi, S
    Nakagohri, T
    Konishi, M
    Kinoshita, T
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 345S - 345S
  • [39] Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC)
    Muszbek, Noemi
    Evans, Rachel
    Remak, Edit
    Brennan, Victoria K.
    Colaone, Fabien
    Shergill, Suki
    Ross, Paul
    Mullan, Damian
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (01) : 147 - 154
  • [40] Sorafenib in advanced hepatocellular carcinoma (HCC) : Ascites as prognostic factor
    Koch, S.
    Niederle, I.
    Gamstaetter, T.
    Schuchmann, M.
    Galle, P.
    Woerns, M.
    Weinmann, A.
    INTERNIST, 2013, 54 (06): : 745 - 745
12345